Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

Cited In for PubMed (Select 19901093)

1.

Antiviral effect of methylated flavonol isorhamnetin against influenza.

Abdal Dayem A, Choi HY, Kim YB, Cho SG.

PLoS One. 2015 Mar 25;10(3):e0121610. doi: 10.1371/journal.pone.0121610. eCollection 2015.

2.

How to approach and treat viral infections in ICU patients.

Kelesidis T, Mastoris I, Metsini A, Tsiodras S.

BMC Infect Dis. 2014 Nov 28;14:321. doi: 10.1186/1471-2334-14-321. Review.

3.

Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.

Park S, Kim JI, Lee I, Lee S, Hwang MW, Bae JY, Heo J, Kim D, Jang SI, Kim H, Cheong HJ, Song JW, Song KJ, Baek LJ, Park MS.

PLoS One. 2014 Jul 3;9(7):e101325. doi: 10.1371/journal.pone.0101325. eCollection 2014.

4.

Influenza RNA-Dependent RNA Polymerase (RdRp) Inhibitors: Potential New Therapy for Influenza Treatment.

Abdel-Magid AF.

ACS Med Chem Lett. 2013 Oct 18;4(12):1133-4. doi: 10.1021/ml400411e. eCollection 2013 Dec 12. No abstract available.

5.
6.

Influenza treatment and prophylaxis with neuraminidase inhibitors: a review.

Kamali A, Holodniy M.

Infect Drug Resist. 2013 Nov 19;6:187-98. doi: 10.2147/IDR.S36601. eCollection 2013. Review.

7.

Favipiravir (T-705), a novel viral RNA polymerase inhibitor.

Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL.

Antiviral Res. 2013 Nov;100(2):446-54. doi: 10.1016/j.antiviral.2013.09.015. Epub 2013 Sep 29. Review.

8.

Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.

Sangawa H, Komeno T, Nishikawa H, Yoshida A, Takahashi K, Nomura N, Furuta Y.

Antimicrob Agents Chemother. 2013 Nov;57(11):5202-8. doi: 10.1128/AAC.00649-13. Epub 2013 Aug 5.

9.

Identification of 23-(s)-2-amino-3-phenylpropanoyl-silybin as an antiviral agent for influenza A virus infection in vitro and in vivo.

Dai JP, Wu LQ, Li R, Zhao XF, Wan QY, Chen XX, Li WZ, Wang GF, Li KS.

Antimicrob Agents Chemother. 2013 Sep;57(9):4433-43. doi: 10.1128/AAC.00759-13. Epub 2013 Jul 8.

10.
11.

Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.

Smee DF, Julander JG, Tarbet EB, Gross M, Nguyen J.

Antiviral Res. 2012 Oct;96(1):13-20. doi: 10.1016/j.antiviral.2012.07.002. Epub 2012 Jul 15.

12.

Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.

Tarbet EB, Maekawa M, Furuta Y, Babu YS, Morrey JD, Smee DF.

Antiviral Res. 2012 Apr;94(1):103-10. doi: 10.1016/j.antiviral.2012.03.001. Epub 2012 Mar 10.

13.

Antiviral strategies for pandemic and seasonal influenza.

Hedlund M, Larson JL, Fang F.

Viruses. 2010 Aug;2(8):1766-81. doi: 10.3390/v2081766. Epub 2010 Aug 20.

14.

Combination chemotherapy for influenza.

Govorkova EA, Webster RG.

Viruses. 2010 Aug;2(8):1510-29. doi: 10.3390/v2081510. Epub 2010 Jul 27.

15.
16.

Animal Models for Influenza Virus Pathogenesis and Transmission.

Bouvier NM, Lowen AC.

Viruses. 2010;2(8):1530-1563.

17.

Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.

Smee DF, Hurst BL, Wong MH, Tarbet EB, Babu YS, Klumpp K, Morrey JD.

Antiviral Res. 2010 Oct;88(1):38-44. doi: 10.1016/j.antiviral.2010.07.003. Epub 2010 Jul 13.

18.

How I treat influenza in patients with hematologic malignancies.

Casper C, Englund J, Boeckh M.

Blood. 2010 Feb 18;115(7):1331-42. doi: 10.1182/blood-2009-11-255455. Epub 2009 Dec 15. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk